Expert: Efficacy of COVID-19 Boosters Against Variants of Concern Is Unknown

Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected.

In an interview with Pharmacy Times, Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected. Adalja said that leaked reports suggest the Biden administration is planning to recommend booster vaccines for adults 8 months after their second dose, and that recommendation could come in the next few days.

Although booster shots could be a necessary step forward in the pandemic, Adalja said he believes it is more important to vaccinate those who are still unvaccinated, rather than focusing all attention on boosting the immune systems of vaccinated individuals. He noted that the vast majority of hospitalized patients with severe COVID-19 are unvaccinated, demonstrating that even just 2 doses of the vaccines are proving effective.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff - stock.adobe.com
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB - stock.adobe.com
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin - stock.adobe.com
Dermatologist examining the skin of a patient | Image Credit: thodonal - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.